Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
BALI PULENDRAN · STANFORD UNIVERSITY · 2024 · $2,168,222 — ABSTRACT – Overall Component In the current proposal we will use a systems vaccinology approach to address two fundamental issues in vaccinology. The first issue concerns the immunology of COVID-19 vaccines, which utilize novel platforms (mRNA) or adjuvants (Matrix M used in the Novavax vaccine). Th…
Kristina De Paris · WEILL MEDICAL COLL OF CORNELL UNIV · 2024 · $1,370,057 — ABSTRACT – Overall Nearly 600,000 new HIV infections occur yearly in adolescents/young adults (ages 15-24 years), the only population in which HIV infections continue to rise. The end of the HIV/AIDS epidemic will be achievable only when an effective vaccine regimen can elicit long-term protective i…
Richard John Martin · IOWA STATE UNIVERSITY · 2024 · $469,119 — Project Summary Filariases are a group of neglected tropical diseases produced by infection with microfilaria of Clade III parasitic nematodes that are transmitted by biting insects. One example is the lymphatic filariasis produced by Brugia malayi. Lymphatic filariasis is a debilitating and disfigu…
Jonathan Lawton · UNIVERSITY OF MARYLAND BALTIMORE · 2024 · $32,456 — PROJECT SUMMARY Despite decades of research, Plasmodium falciparum malaria continues to kill hundreds of thousands of children in sub-Saharan Africa each year. Vulnerability to severe malaria is complex, involving both host and parasite factors. Blood type A is an established risk factor for severe …
Swaminathan Smita Iyer · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · 2024 · $737,761 — Project Summary This proposal aims to enhance HIV prevention with a vaccine approach that promotes durable immunity. The studies center on CD4 T helper cells within lymph nodes, crucial for humoral and cytolytic memory. Our objective is to induce robust CD4 T follicular helper (Tfh) cells as they ar…
MAHADEVAN Raj RAJASEKARAN · VETERANS MEDICAL RESEARCH FDN/SAN DIEGO · 2024 · $215,250 — ABSTRACT Fecal incontinence (accidental leakage of stools; FI) is a major medical illness, occurs in a significant population of women (>7%) and is under reported. Most common cause of FI is childbirth related injury to the external anal sphincter (EAS), pelvic floor muscles and pudendal nerve (PN) …
Norbert Pardi · UNIVERSITY OF CALIFORNIA LOS ANGELES · 2024 · $628,499 — ABSTRACT The remarkable effectiveness of the COVID-19 mRNA vaccines heralds a transformative immunization platform against viral infections. A key innovation—recognized with the 2023 Nobel Prize—is the replacement of uridine (U) with N1-methylpseudouridine (m1Ψ) in their mRNA constructs. This substi…
Yogesh K Gupta · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · 2024 · $172,636 — ABSTRACT The massive global pandemic with high morbidity and mortality makes Severe Acute Respiratory Syndrome coronavirus-2 (SARS-CoV-2) one of the deadliest viruses in recent history. It is especially noteworthy for hijacking the normal operations of human cells. To develop effective therapies, we…
Elias Sayour · UNIVERSITY OF FLORIDA · 2024 · $601,230 — Project Summary While activated T cells cross the blood-brain barrier (BBB), immunotherapy has yet to be harnessed for targeted therapy due to GBM’s heterogeneity and immunosuppressive microenvironment. Unleashing immunotherapy against GBM requires new technologies that activate the tumor microenvir…
Xiaobo Zhou · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · 2024 · $351,000 — The COVID-19 pandemic has presented new challenges to individuals world-wide. Since the first reports of infections in the US more than 90 million individuals have become infected and more than 1 million have died. SARS-CoV-2 genome has various open reading frames (ORFs) encoding 16 non-structural p…
Xiaorong Lin · UNIVERSITY OF GEORGIA · 2024 · $226,500 — Abstract Cryptococcal meningoencephalitis is responsible for 15% of the total deaths of AIDS patients. There is no vaccine available for cryptococcosis and the disease claims hundreds of thousands of lives each year, with the global mortality rates of ~70% despite current antifungal therapies. The …
Beatrice H Hahn · UNIVERSITY OF PENNSYLVANIA · 2024 · $879,161 — PROJECT SUMMARY (See instructions): A central goal in HIV/AIDS vaccine research is the elicitation of broadly neutralizing antibodies (bNAbs). Here, we leverage three recent discoveries from our groups to generate more effective V2 apex immunogens. Having found that unshielded regions (“glycan hol…
Paul Bates · UNIVERSITY OF PENNSYLVANIA · 2024 · $577,453 — Severe Fever with Thrombocytopenia Syndrome virus (SFTSV) is a pathogenic, tick-transmitted bunyavirus that can cause a severe febrile hemorrhagic-like disease with case fatality rates of up to 30%. Discovered during a 2009 outbreak of febrile illness in China, the geographic distribution of SFTSV e…
Laurie Ann Rumker · HARVARD MEDICAL SCHOOL · 2024 · $46,918 — Project Summary/Abstract Tuberculosis (TB) remains the global leading cause of death from an infectious agent. Understanding why some patients present with early symptoms while others develop latent infections is critical for combating this illness. While environmental factors are known to elevate …
Gaurav Sahay · OREGON STATE UNIVERSITY · 2024 · $625,649 — ABSTRACT Inherited retinal dystrophies (IRDs) are a heterogenous group of orphan diseases, inherited in an autosomal dominant, recessive or X-linked pattern in addition to mitochondrial transmission, all leading to the loss of functional vision and often progressing to blindness. As a group, IRDs ar…
Thomas Siegmund Postler · INTERNATIONAL AIDS VACCINE INITIATIVE · 2024 · $448,768 — Project Summary/Abstract Tuberculosis remains one of the top ten leading causes of death worldwide (1). Based on the most current information from WHO 2020 report, in 2019 an estimated 1.4 million people died from TB and approximately 10,000,000 fell ill (2). The COVID-19 pandemic has led to massive…
Harvey Michael Friedman · UNIVERSITY OF PENNSYLVANIA · 2024 · $812,498 — Abstract Genital herpes affects 650 million people globally. Vaccines are urgently needed to prevent infection and treat individuals already infected. During the current funding cycle, we developed a candidate vaccine for preventing genital herpes that uses nucleoside-modified mRNA encapsulated wit…
ROBERT J FONTANA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · 2024 · $374,400 — ABSTRACT Over the past 5 years, the DILIN Prospective and Retrospective studies have led to significant improvements in DILI causality assessment (e.g. RECAM, HCV/ HEV testing) and improved understanding of the risk factors and outcomes of DILI due to individual drugs and HDS products. Mechanistic i…
Peter Shen · NORTHWESTERN UNIVERSITY AT CHICAGO · 2024 · $678,119 — PROJECT SUMMARY/ABSTRACT Although smallpox was formally declared to have been eradicated in 1980, molluscum contagiosum is widespread and a variety of zoonotic poxviruses continually infect and adapt to humans. This is exemplified by monkeypox/Mpox virus, which causes outbreaks in humans with increa…
Adam Tuttle · ENTERX BIOSCIENCES, INC. · 2024 · $294,052 — Project Summary Inherited retinal diseases (IRDs) are a heterogeneous group of genetic diseases that lead to loss of vision and often progress to blindness. As a group, IRDs are linked to over 280 genes and affect ~4.5 million people worldwide. In all IRDs, the ultimate cause of vision loss is degen…